KRAS cancer treatment advanced Monday as Johnson & Johnson agreed to pay $1 billion for Firefly Bio's Firelink platform, a degrader antibody conjugate that destroys KRAS proteins rather than blocking them — targeting pan-KRAS mutations in pancreatic and colorectal tumors that current inhibitors cannot reach.
KRAS Cancer Treatment: J&J Acquires Firefly Bio for $1B to Destroy, Not Block, Tumor Protein
